SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > Free Zone > All Trading - Technical >


RSS Feed
      Hide Sticky   Hide Intro
Moderator: kiy Assistants:
Search This Board: 
Last Post: 5/27/2017 9:54:01 PM - Followers: 2 - Board type: Free - Posts Today: 2

 ( can click on..."Hide Intro" get to the message board...this page is rather long...) 

Speculation Stocks ...
There isn't a day that goes by on Wall Street when certain stocks trading for under $10 a share don't experience massive spikes higher. Traders savvy enough to follow the low-priced names and trade them with discipline and solid risk management are banking ridiculous coin on a regular basis. Roberto Pedone...
Just be careful... Pumps & Dumps 101
Lesson #1 – The cover up is often worse than the original problem. Don’t expect them to admit it.
Strategy #1: “The best way to expose a liar is to just let them keep talking”.
Strategy #2: “Make sure to give the guilty party enough rope to hang themselves”.
They took a company with essentially no business operations and little revenue and deceived the market and their clients into believing it was worth hundreds of millions of dollars through a dizzying round of unauthorized trades and deceptive promotions. In the end, the deceived investors were left holding the empty bag,”

Some RULES for this I-Hub Board...........

This board will be used for analysis of charts ranging in different time periods to determine signals for trading of various instruments=individual stocks, etf's and options. Please direct your comments towards technical indicators that everyone can see on a price chart:  we are talking about signals and technical indicators here, not opinions or predictions or forecasts of  when the next grand slam will be... share technical signals and charts with the group and if you have an active position......  Rather than being opinionated and letting your subjective bias determine which side of the market to be on,  try to maintain objectivity based on technical analysis. 
 One of the key items to remember as investors/traders is that the market doesn't always reflect reality. Oftentimes it reflects belief. And belief can prove to be a delusion. 

"A belief held without objective examples that everyone can see is a delusion."
“Opinion is that exercise of the human will which 'lets' us make a decision without objective information and objective examples.” And is obviously ....not the best choice that promotes a healthy process.
“Discussion is an exchange of knowledge; an argument an exchange of ignorance.”
Understand the above and you will understand the phrase..."Self will run riot" and you can expect  the results  of this riot will be destructive for yourself first and then for others.
Dysfunctional attitudes and behaviors = "self will run riot" it is not a process that builds "character".  It is not common decency, nor  any form of can only be destructive. 

It is no disgrace to be wrong... disgrace happens when you choose to stay wrong...
Building character is a project you never complete.
We form our character in defining moments because we commit to irreversible courses of action that shape our personal and professional identities. We reveal something new about us to ourselves and others because defining moments uncover something that had been hidden or crystallize something that had been only partially known. And we test ourselves because we discover whether we will live up to our personal ideals or only pay them lip service.

If you feel you must GAMBLE and encourage gambling from the 5 minute or lower time frames you will be asked to take  your message to the "gamblers board"...If you feel you  "must  offer an opinion or off topic comment; please do it after trading hours. Charts and signals at signal lines is what we want...and If you feel you do not need to answer questions on this board ...then why are you here.
I-Hub's rules state:  It is the burden of each poster to ensure that their posts do not contain content that qualifies them for removal. It doesn't matter if your post contains the cure to the common cold or the best stock tip since (fill in your favorite ticker here), if it contains other content that is a violation of the site's rules of conduct, then it qualifies for removal.  ...
Thank You...                         You are only as good as your next trade...Kiy
This release may contain "forward-looking statements" that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as "may", "will", "aim", "will likely result", "believe", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", "seek to", "future", "objective", "goal", "project", "should", "will pursue" and similar expressions or variations of such expressions. ...

Always trade with the direction of the daily CCI 
Swing trades=  Always trade in the direction of the daily bias even for short term trades...if you really feel you must trade against the daily need a hair trigger...get out quick if the position moves against you. The Average True Range for SPX usually runs around 15 points. This range inceases as volatility increases
Remember...What you're looking at on an intraday chart is a daily candle or OHLC price bar "uncompressed" from the daily chart. Kind of a "micro" view of the Macro daily chart...and daily would be a micro view of the weekly chart... 
Front Running a Daily chart signal (...The 60 minute chart can be considered as a proxy for the daily chart and will lead daily chart signals when daily CCI is getting ready to come out of oversold overbought just takes patience to get the timing..) This way; rather than only trade the intraday cycle you can use the intraday charts to front run a daily CCI signal. When the Daily CCI is ready to move out of oversold or overbought... your goal eventually is to catch a trade from intraday that carries over onto the daily chart. It just takes some practice and patience becoming comfortable with the CCI cycles= Intraday/Daily/Weekly and as the 3cycles sometimes line up together= synchronized you may consider a larger position. Best trades will be trades that are trading in the same direction as the daily chart's bias...=Commodity Channel Index CCI 20 points the way...

There is a "Method to the Madness of Crowds" and you can find it and define it on the charts...Technical Charting takes away some of the fear/doubt in trading... and then all you need is patience while waiting for the chart to tell you when the bias/momentum/sentiment turns...listen to signals at signal lines(simple enough...yes?...)...Kiy...

The Market is a giant feedback loop, showing traders (and anyone who views the market) a thermometer reading of the social mood under which traders, and by extension society,  are operating. Most traders seem to think of the market is something that has some external value outside of the price attributed to it by traders. I prefer to think of it as a real-time gauge of a society’s view of their own productive capacity…or more simply put–social moodWhen Markets are understood, the idea that everyone can make money is not only inaccurate but impossible and laughable. Everyone making money means there is no market, because who would be willing to taking the other side of the trade? In addition, most traders feel they can move with the crowd to make a (paper) profit, and then get out before the crowd, turning that trade into a real profit. In theory this is sound, but remember everyone else is setting out to do the same thing. It is this crowd movement which allows traders to make money at times. Without a large portion of traders coming to the same decision markets simply would not move. It takes conviction by many traders to create a trend, then it takes euphoric acceptance that “this is the new norm” to end it and “bend it. ” It then takes mass disillusionment to crash it the other way. (

Regression to the Mean is the most powerful law in financial physics
Mean reversions out of extremes are the most powerful and profitable forces in all the financial markets. Riding one has enormous benefits for your wealth.
Financial-market prices and sentiment are like a giant pendulum. The farther they are pulled to one extreme by excessive greed or fear, the farther they necessarily swing to the opposite extreme in the subsequent mean reversion. Like pendulums, these reversions don’t magically stop right in the middle at normal again. Their kinetic momentum carries them through to the opposite ends of their arcs. But overshoot extremes don’t last for long, as the universal greed necessary to fuel them quickly burns itself out.

Markets are not about beliefs, but about sentiment. And, if you can track sentiment, If you can measure sentiment... then you are in a position to make your investment account grow without the need for excuses.  (...this really is all you need to know about the Markets; ...
Color Code of stock symbols/letters....MVIS  (T/$3.50H-4.50) example MVIS leter colors indicate the stock price is pointing down and all the letters are boxed in with green= oversold MVIS=MVIS  and you should be looking/considering a long position...(T/$3.50H-4.50) and someone has put a $4.50 price target on it.  (..."T"=target price...the "H" indicates the first target price has been hit...  
Colors are based on reading the CCI 20 (Commodity Channel Index signal lines) ... if "letters" are colored =Green =UP...Red=down...lighter colors = less confident in direction...if letters/stock symbols are Boxed in=Green =oversold=anticipate an "UP" cycle for the CCI 20 indicator or a mean reversion price bounces = at least to centerline within the Bollinger Bands 20,2= the 20 day moving average... and if the box is red=Red=overbought=anticipate a "DOWN" cycle...
§=Reverse of a Signal line(focus is the technical indicator CCI centerline...overbought line +100 and oversold line -100)... ¥= first stock to turn UP/Down after the Group/Sector has been overbought/oversold. Stocks that have a "Target" price are the better choice for a trade...example...MVIS  (T/$3.50H-4.50) a target price with an "H" behind it says the target was "hit" since the target price was MVIS has a second target price of $ if you find MVIS oversold you can consider a long position if you are comfortable with the width of the Bollinger Bands and the target price will give you 10% or more profit... remember this; PRICE= %B and CCI they indicate very much the same and they represent price within the parameters of the Bollinger Bands (box Price inside the Bollinger Bands. The %B tends to lead the CCI signals (a little)...

A few of the more interesting ETFs/Sectors ...Candle Glance Charts= click on the ETF's symbol and you'll get a set of the largest holdings 10-12 stocks in that ETF.
XLK CandleXGlance AAPL,MSFT,FB,T,GOOGL,GOOG,VZ,V,INTC,CSCO .............. HDP (T/$21)
SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC  ...INTC ...§AMD (T/$11H-17

BOTZ...Global Robotics and Artificial Intelligence.. ISRG,MBLY,TRMB,JBT,IRBT,BRKS,FARO

WEAR wearable technologies/components IRTC,DXCM,BSX,AAPL,GGNDF,BEAT,KN,TASR,PODD,ABT ( doesn't have a chart yet.05/01..)
wearable devices that will ship this year to enterprise customers from public companies including Fujitsu (OTCPK:FJTSY), Vuzix (NASDAQ:VUZI), Google (NASDAQ:GOOG), and Intel (NASDAQ:INTC):
Market estimates vary widely, but a recent report by Grand View Research estimates the enterprise wearables market will be valued at more than $20B by 2025. If RealWear disrupts this new market with the HMT-1 and secures dominant market share as an industry standard device, shipments could exceed 1M units annually well before 2021. Once shipments exceed 400K units annually, the benefit to Kopin (KOPN) becomes tangible on a per share basis.

SKYY CandleGlance Cloud Computing ...AKAM,ORCL,EQIX,NTAP,AMZN,CSCO,OTEX,JNPR,FB ....YEXT (T/$14H-18) 4 Brookers like this...
PRNT 3D Printing

SEA CandleGlance Shipping TNK,EURN,TGP,NMM,SSW,SFL,TK,TNP, ... SEA vs. VALE 

CGW Global Water Index... BGERF,AWK,DHR,PNP,XYL,IEX.......  (CDZI...Water Utility)

Xylem Inc (NYSE:XYL) is a major provider of water industry engineering solutions. The company has a large presence in China as well. Increasing urbanization, coupled with a massive population, could be a recipe for water supply disaster in China.
Pentair plc. Ordinary Share (NYSE:PNR) specializes in all things water. The company provides products and services in water purification and filtration. Additionally, PNR provides irrigation management, desalination and aquaculture systems services.
According to Pictet Asset Management analyst Arnaud Bisschop, 
water filtration is key. PNR’s consumer-targeted water filtration products may soon be the best option for people living in regions lacking clean water.
SLX...CandleGlance ...RIO,VALE,TS,NUE,PKY,MT,SID,WOR,VEDL,GGB...  JJU  Aluminum CandleGlance ...AA,ACH,CENX,KALU

Speculation Stocks 
Virtual Reality/Augmented Reality/Artificial Intelligence
In the real world, Artifical Intelligence9(AI) will enter our lives in three phases and forms:
PHASE #1 Assisted Intelligence: AI that replaces repetitive and mundane tasks traditionally done by humans. A timely example would be the proliferation of robots used at Amazon to “pick” items from warehouse shelves, which we mentioned in last month’s issue. You’ll recall we’re already booking double-digit gains in the space (with more to come) in the Robo Global Robotics & Automation ETF (ROBO) and Cognex Corp. (CGNX).

PHASE #2 Augmented Intelligence: AI that incorporates machine learning to supplement and support human analysis. One area where this type of AI is being implemented is legal discovery. That is, the period of time in which both legal parties gather evidence. Seventy-five percent of the costs associated with discovery are tied to human review of documents. And people are expensive. Using AI to pre-screen — and reduce the amount of relevant documents before humans even start reviewing the files — can dramatically reduce costs. We profited from this very technology when our portfolio position Epiq Systems was acquired for a 40% gain in July 2016.

PHASE #3 Autonomous Intelligence: AI that takes over for humans in a highly specific task. Self-driving cars would be the ultimate example of this in action.

02/28/17 ...potential profits in the VR/AR industry are enormous. Goldman Sachs (GS) estimates that the market will reach $80 billion by 2025, with the potential for that figure to actually soar much higher, to more than $180 billion.
Many of the companies developing VR/AR hardware and software are among the biggest names in Silicon Valley including
 Apple (AAPL), Alphabet (GOOG), Amazon (AMZN), Facebook (FB) and Sony (SNE).
On a July 26, 2016 conference call with analysts, AAPL's CEO Cook said he was bullish about augmented reality. "AR can be really great, and we have been and continue to invest a lot in this," Cook said. "We are high on AR for the long run. We think there are great things for customers and a great commercial opportunity." In September, Cook told ABC News that augmented reality presented a bigger business opportunity than virtual reality. "There's virtual reality and there's augmented reality — both of these are incredibly interesting," Cook said. "But my own view is that augmented reality is the larger of the two, probably by far."

Augmented reality superimposes digital images in a person's field of vision. It provides the user with information for navigation, to complete tasks and other purposes. By contrast, virtual reality is an immersive media that places the wearer of special headsets into a completely digital world, mostly for entertainment purposes. In November, Bloomberg reported that Apple had already ordered "small quantities of near-eye displays from one supplier for testing." It said Apple was in the exploration phase of wearable computing. The device being tested would connect wirelessly to the iPhone. Also in November, KGI analyst Ming-Chi Kuo said Apple is looking to leapfrog the competition in AR by three to five years with its offering. But Kuo said it could take Apple one to two years to come out with an AR product.
 In the Year 2525 ....Sony Facebook's Oculus virtual reality device Samsung, Microsoft Hololens...Google Glass 

HIMX 6.76(T/$7H-9H now $12) ...hyped as the I-PHONE KILLER...semicndtr, display driver integrated circuits (ICs), timing controllers used in televisions (TVs), laptops, monitors, mobile phones, tablets, digital cameras, car navigation, et al...(buy after 2nd quarter 2017...)

*****KOPN 3.40 (T/$5) Kopin Corporation semicndtr...wearable technologies and display products...develops, makes and markets virtual and augmented reality gaming, training, and simulation products. Kopin’s Whisper Voice Chip, Solos smart glasses and Pupil LCD display modules will be among the Kopin products displayed on the CES show floor. 

Kopin has transitioned to a wearable-centric company - they have positioned themselves to be entirely levered to success in Enterprise and Consumer head-worn AR with components and licensable IP.

When you combine high level AR market forecasts with Kopin's device share dominance with design wins inside 5 Industrial AR headsets, I believe it is clear this stock is the one to own if you are looking to lever your portfolio to the massive growth possible in the head-worn wearable segment.

As I have noted previously and pointed out in my blog posting "The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following:

 "The Wearables Acquisition Intel Needs To Make - And Fast!" I believe a current reasonable market capitalization value for Kopin would be $394M or north of $5.00/share based on the following:

  • IP portfolio I have valued at at least $300M: Kopin holds over 300 granted & pending wearables patents; I believe they possess the strongest head-worn wearables IP portfolio in the industry

   LPL  ...LG Display
MVIS 2.90 (T/$3.50-4.50) Microvision makes PicoP scanning technology for three-dimensional sensing and image capture.
IMMR 9.15 WEAK 60MIN(T/$8H-13) Immersion Corporation...the creation of the sense of touch to the user through the use of vibrations or motions. Immersion is one of the leaders in this technology, also known as kinesthetic communication. (very weak guidance for all of 2017)
*****OCLR 9.38(T/$11H-15) lasers and optical components partner with CEIN...Oclaro provides differentiated solutions for optical networks and high-speed interconnects driving the next wave of streaming video, cloud computing, application virtualization and other bandwidth-intensive and high-speed applications....

 NPTN 9.60 (T/$13-17) NeoPhotonics high speed digital optical signals...  FN ...*FNSR (T/42) ... 

Head worn devices...ZBRA Zebra Technology... INTC Intel...FJTSY Fujitsu... 
***** Vuzi 5.00(
VUZI eyeglasses ...
****NEON 1.10 (T/$3.50)...touch screen and ability to sense an object's size,deph,velocity, pressure, proximitty to any type surface....
SYNA ...ACIA... AAOI...  LITE (T/45H) ... 

INTC 37.00(T$38-42) ..Buyout ..03/13 =Mobileye...*MBLY Triple Digit Stock  develops computer vision/machine learning/data analysis/localization/mapping for advanced driver assistance systems and autonomous driving technologies primarily in Israel.... Mobileye...We believe the stock’s reaction to the Tesla news was an overreaction because 1) Tesla comprises about only 1% of Mobileye’s revenue today 2) Mobileye said that of its $1.1BN 2019 revenue target, Tesla contributes ~2% (or ~$17MM on 350K cars).” Anderson sets a $60 price target; the stock is rebounding, up $2, or 4.4%, at $47.33. Anderson writes that his own digging suggests the split had been in the works for some time, and that graphics chip maker Nvidia (NVDA) is likely being tapped by Tesla to produce an alternative: Our sense from talking with industry sources is that the relationship between Mobileye and Tesla has been headed to this outcome for some time. We believe Tesla would like to push the envelope more with autonomous features and increasingly with their own algorithms. Our best guess at this point (based on our checks) is that Tesla will eventually migrate to a hardware solution from Bosch with processing done by Nvidia using internally-generated Tesla algorithms.

Intel (NASDAQ:INTC) has been very active acquiring companies involved in the burgeoning wearable technology segment. You will find a great overview from Matt Margolis in his article entitled, "Intel Is Quietly Emerging As The Augmented Reality World Leader." Despite this acquisition activity, there are still significant gaps if Intel wants to repeat the "Intel Inside" strategy for wearables that it so successfully employed in the PC era.

In my opinion, these are the missing pieces from Intel's current wearables ecosystem:

  • Proven high yield micro display and complementary optical technology
    Next generation noise cancellation hardware and software
    Head-worn reference designs - the new Intel Inside motherboard!
    Licensable user interface IP covering voice and gesture input methods
    Software middleware or a wearables operating system
    Broad wearables patent protection

Interestingly, there is a way for Intel to achieve gap closure in all of the areas above with a single transaction: they could acquire Kopin Corp. (NASDAQ:KOPN).

Assuming Intel is as interested as I think they should be, what would this transaction look like and how can we benefit?

VSH 15.90 weak...(T/$15H=16.25) Vishay Intertechnology ...broadens its optoelectronics portfolio with the introduction of a new high speed silicon PIN photodiode with enhanced sensitivity for visible light. Vishay Semiconductors VEMD5080X01 offers fast switching times and low capacitance for precise signal detection in wearable devices and medical, industrial, and automotive applications.
*ISNS 3.60... Image Sensing Systems, Inc. develops and markets software-based computer enabled detection products and solutions for the intelligent transportation systems industry. Its video and radar processing products are used in traffic, security, police, parking applications, such as intersection control, highway, bridge, tunnel traffic management, venue security, entry control, LPR, traffic data collection. 
**NVDA  Nvidia neural imprinting and all forms of virtual reality...  ...Tesla’s co-founder and CEO, Elon Musk, has promoted NVIDIA’s GPUs as a key element for driverless car technology. At the 2015 GPU Technology Conference last year, Musk said that what NVIDIA is doing with its Tegra GPU’s will prove “really important for self-driving in the future.” While Tesla uses NVIDIA’s GPUs, it doesn’t currently use NVIDIA’s Drive PX system, though there’s no reason why it couldn’t in the future. Why all of this matters for NVIDIA investors NVIDIA’s self-driving car focus is becoming increasingly important because of the technology’s quick adoption by both automakers and consumers. IHS Automotive estimates that between now and 2035, there will be 76 million vehicles on the road with some level of self-driving capabilities. Cheaper technology is spurring growth, as is evidenced by Honda’s $20,040 Civic, which can drive itself on the highway. The driverless-car market is expected to grow to $42 billion by 2025, according to Boston Consulting Group, and it’s clear that NVIDIA’s mapping out a plan to grab as much of that market as possible with its current automotive partnerships.
******GSIT 8.55 (T/$9H)  Remember how Nvidia leveraged the benefits of “parallel processing” to net windfall sales and profits for investors in 2016? Well, GSI’s in-place associative computing chips will leverage “massive parallel processing” capabilities. Think Nvidia on steroids.

*****HEAR 0.96(T/$1.90) 4D sound...

Semi/Cloud/Biometrics 02/11...  
MODN 12.50(T/$16) ...provides revenue management cloud solutions for the life science and technology industries
**HIVE 3.70(T/$9-10) cloud-managed mobile platform...
EIGI 8.10 (T/$10.50)... TWLO
DTRM 3.40 (T/$5) ...Determine Cloud Platform continues to set the standard in what constitutes a true source-to-pay cloud platform. It provides modular, best-of-breed solutions on a single platform, seamlessly integrating solutions, workflows and data to empower decisions and results.
****STM§16.32 (T/$14H-$20)  STMicroelectronics Semicndctr 
XTLY 11.40(T/$15-20) incentive compensation solutions for employee and sales performance management 
***PSTG 11.90  (T/13-15) Provides flash memory-based enterprise storage hardware...
PURE 03/02...Pure Storage continued its streak of revenue and earnings beats, the company's guidance for the first quarter was disappointing. It expects to produce revenue between $171 million and $179 million, up just 25% year over year at the midpoint and well below analyst expectations of $201.7 million.
Pure Storage expects to produce $1 billion of revenue this year, right in line with the average analyst estimate, but the weak first-quarter guidance will require growth to pick up as the year goes on. CEO Scott Dietzen sees opportunities going forward:

Pure Storage is delivering the data platform for the cloud era, helping customers put data to work for their businesses. This year, Pure expects to reach $1 billion in revenue -- a remarkable achievement and evidence that we're only just getting started. We could not be more excited about the opportunities ahead.

Shares of Pure Storage are now down about 50% since peaking soon after the company's IPO in late 2015. With growth expected to slow during the first quarter, and with profitability nowhere in sight, investors are clearly losing patience.
CUDA (T/$25h-29) Barracuda ... cloud-enabled solutions that enable customers address security threats, improve network performance, and protect and store their data. It provides various security solutions, including Barracuda Email Security (01/09 earns/profit beat)
****ANY 0.17(T/$1.50) tech. cloud, storage... ****USAT5.10 (T/$6) wireless networking, cashless transactions, asset monitoring...
***FTR 1.20 (T/$4.00) telecom fiber-to-the-home and cloud backup, sharing, identy protection...
CNIT..Internet service company that provides cloud-based platform China...
*NXTD (T-$4) biometrics security mobile devices, electronic wallet  virtually any magnetic stripe card allow single electronic card to replicate cards for  MobileBio VoiceMatch ...
***ADI... Biometrics, drones

Other Tech Stocks
***PRCP (T/$11)Perception Inc... 3D scanning products, laser scanners ...
**GSB software cloud based(T/?)
****PYDS electronic payment... . *CPST 0.64Capstone Turbine... microturbine...
§*****WATT WATT  Energous...wire-free charging of electronic devices at a distance...
As for the iPhone 8, one of the main rumors so far is related to the inclusion of wireless charging technology in the phone. Wireless charging is an interesting concept, and current options rely on magnetic energy to charge, requiring users to place their device on some sort of compatible pad. Energous Corporation WATT, an innovative wireless charging company that uses RF waves to charge. Energous promises “long-distance” wireless charging, and many people think the company could be teaming up with Apple to incorporate the tech in the iPhone 8. (

IWSY  ImageWare Systems...biometrically enabled software-based identity management ... 
VEEV Veeva medical research...PIRS ...anemia treatment...
AMBA (T/$84)... Ambarella produces systems on a chip for various camera applications such as GoPro action cams and drones. These chips incorporate numerous patented technologies that allow them to work with very low power, in low ambient light conditions, and with highly efficient compression capabilities. 
PI (T/$40h)  Impinj frequency ID chip-maker, maker of RAIN RFID chips which helps supply chains frictionlessly track items...
MU Micron is the third largest mobile DRAM and fourth largest NAND manufacturer in the world. It's arguably the most straightforward play on the memory-chip market for investors, Samsung Electronics (NASDAQOTH:SSNLF), and Western Digital (NASDAQ:WDC)  icron is currently developing next-gen memory technologies such as 3D NAND and 3DXPoint with Intel (NASDAQ:INTC),

BIO/Pharma/Medical ...

OMER... (T/$15H-22) 
CLBS 5.30 (T/$7) ...provides development and manufacturing services to the cell therapy industry in the United States... also developing CLBS03, a T regulatory cell clinical Phase II therapy targeting adolescents with type 1 diabetes. 
CGEN (T/$9-14) ... early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types 
*****IMDZ (T/$16-18) ... a prime-boost vaccine approach against NY-ESO-1-expressing tumors, designed to generate an integrated, anti-NY-ESO-1 immune response in vivo via a targeted, specific interaction with dendritic cells, a mechanism of action Immune Design believes differs from traditional cancer vaccines. 
GLYC ()...leukemia drug ...rocket because of FDA breakthrough designation
***AXSM 3.80 (T/$14) track designation Tx for agitation in patiennts with alzheimer disease...
*****ARNA 1.15 (T/$5)  ...weight loss drug...pulmonary arterial immune disease...ulcerative colitis
PGNX 6.50  (T/$14) A neuroendocrine tumor affects the hormone-producing cells of the body’s neuroendocrine system that comprises of cells which are a combination of hormone-producing endocrine cells and nerve cells. These cells control the flow of air, blood and food through the different body parts. There are no approved therapies available in the U.S. market for the two diseases.
OCRX...Ocera Therapeutics (T/$3-4)treatment of hyperammonemia and resultant hepatic encephalopathy 
***BPMX. 0.45..(T/$3) ...suggests that molecular iodine can specifically inhibit cellullar proliferation and drive cell death in certain breast cancer cell lines without apparent toxicity to normal breast cells.
GERN (T/$5)... lead candidate, imetelstat, appears to have an important advantage over the leading treatment (Jakafi) for a rare form of blood cancer known as myelofibrosis, a disorder marked by overactive blood cell production in bone marrow. In a trial that enrolled 33 myelofibrosis patients, Geron's imetelstat generated a clinical response defined in part by an observed improvement on bone marrow damage among about 21% of patients. Furthermore, 12% experienced a complete remission defined by complete reversal of damage.
ACHN (T/$10)...Achillion Pharm ... ***IDRA (T/$4-8) cancer rare disease..
EXAS ...(T/27H) Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer 
 MNTM 0.27 Anti-Aging Drug ....SRNE...Sorrento Therapeutics
ONTX 2.00 (T$5.00) Onconova targets RAS cellular pathways which have been linked to cancer cells while causing minimal damage to healthy cells. 
****OMED 3.50 (T/$9) OncoMed Pharm...anti-cancer stem cell (CSC) and immuno-oncology therapeutics... Lung...Ovarian...Colon... 
ROKA (T/$10)(NEW LOW 3/17)Roka Bioscience molecular assay technologies for the detection of foodborne pathogens 
***SNDX (T$/27) ...pipeline of combination therapies in multiple cancer indications. Our lead candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Syndax is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma; with Genentech, Inc. for TNBC; and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.
EBS...(T/$40) Emergent BioSolutions,Biodefense division... BioThrax to treat anthrax disease; Anthrasil treatment of inhalational anthrax; BAT treat botulinum disease; VIGIV address adverse events from smallpox vaccination; RSDL removal or neutralization of chemical agents, T-2 toxins, and various pesticide-related chemicals from the skin. NuThrax, next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 compound in the EV-035 series of broad spectrum antibiotics for Burkholderia pseudomallei; VAX161C, a recombinant pandemic influenza vaccine; PreviThrax, a recombinant protective antigen anthrax vaccine, as well as other products addressing public health threats and emerging infectious diseases. Its Biosciences division markets IXINITY prevent bleeding episodes in people with hemophilia B; WinRho SDF treat autoimmune platelet disorders and hemolytic disease of the newborn; HepaGam B post-exposure prophylactic treatment of hepatitis-B; VARIZIG post-exposure prophylactic treatment of varicella zoster virus. This division's investigational stage product candidates include otlertuzumab, protein therapeutic for Chronic Lymphocytic Leukemia; MOR209/ES414 metastatic castration resistant prostate cancer under collaboration with MorphoSys AG; ES210, a protein therapeutic for inflammation-related indications; 5E3, a monoclonal antibody therapeutic for Alzheimer's disease; and other protein therapeutic product candidates primarily for the treatment of immuno-oncology. The company also provides contract manufacturing services to third-party customers.
****FBIO (T-9) Fortress Biotech, Inc., a biopharmaceutical company, develops novel immunotherapy agents for the treatment of autoimmune diseases and cancer. Its product includes CNDO-109, a lysate that activates donor natural killer cells for the treatment of cancer-related and other conditions.
**INFI 1.70 (T/$2H) treatment of blood cancers... 
**ROSG (T/$3.50H)(1:12 REVERSE SPLIT 03/17) Rossetta Genomics... MicroRNAs are a group of genes that are produced using instructions encoded in DNA.
*****ONCS (T/$3-5)5/18  ...gene therapies...electroporation delivery device, melanoma...
§ARRY 7.80 (T/$10H) Array BioPharma  Many drugs in the pipeline cancer...hepatitis C virus...myeloma and many gene cancer inhibitors...
*****CMRX 4.60 (T/$8) oral antivirals herpes virus and adeno virus.
*MRNS (T/$3) biopharm epilepsy and neuropsychiatric disorders... 
ATOS biopharmaceutical breast cancer Seattle... ***DMPI 2.22 DelMar Pharmaceuticals Inc. lung cancer,brain cancer...
***ENDV (T/1.50)... Bioelectronic device, treat acute liver failure (ALF) and other inflammatory conditions in vital organs ... stem cells...
 SSH  (T/) early-stage medical device,cardiac and coronary diseases 1 for 30 reverse split Jan. 13......
CHEK 1.98(T/$5-6) medical diagnostics company, engages in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening for precancerous polyps and cancer...
***APDN (T/$6-8) Applied DNA Sciences Inc. *****QURE 4.80(T/$8-12) Gene Therapy...
CALA  (T/$9H)...small molecule drugs directed against tumor metabolism and tumor immunology targets...
****SBOT (T/$4)... Biotech...keyhole limpet hemocyanin (KLH) protein...  POTENTIAL GAME CHANGING TREATMENTS OF SERIOUS DISEASES...When you're developing a vaccine for any indication, you can have a dendritic cell vaccine, you can have a DNA-based vaccine, you can have a KLH-based vaccine or a peptide vaccine, and each one has its own advantages, disadvantages and attributes that you may or may not want as part of the immune response you are targeting. KLH seems to be geared toward generating antibody responses versus T-cell responses. 
NVAX (T/$1.50) (insider buying 05/11) recombinant nanoparticles vaccines...
FOLD  AMICUS Therapeutics...biotech rare diseases... CLDX... OPK ...
NEOT Neothetics...LIPO-202 phase 2 TRIALS. ..  QBIO story stock glaucoma drug...
TTNP Pharma... treatments for chronic diseases, such as Parkinson's disease. The company offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the medicine buprenorphine in patients for six months following a single treatment.
*** MNKD commercial-stage diabetes drug and device maker.
**BCLI adult stem cell therapies for neurodegenerative disorders ALS...
*NNVC nano-biopharmaceutical viral infections, shingles cream will be its first drug to start human testing...
 **HEB biotech for the treatment of viral and immune based chronic disorders...chronic fatigue syndrome=myalic encephalomyelitis
***MHTX () nanomedicine... THLD biopharmaceutica sm molecule targeting cancers that over express a particular enzyme...   
*ONVO  ONVO human tissues that could be employed in drug discovery and development,  tissue patches for repair or replacement damaged tissues/organs... tissue assay toxicities would help companies not have to run Phase 1 trials...
**LBIO (T/$11-18) adoptive cell therapy using tumor-infiltrating lymphocytes  treatment of metastatic melanoma, bladder, lung, breast, and HPV-associated cancers.... (many law suits recently)
CATB (T/$9)...?
*PRAN biotech development of therapeutic drugs in Australia... AKTX  Akari Therapeutics...Biotech tx rare autoimmune and inflammatory disease
*OBMP () Bio cancer vaccines...
KPTI (T/$15)  Karyopharm's blood cancer hopeful. Selinexor is a first-in-class oral treatment slated for a large, late-stage combination study with multiple myeloma patients also receiving Velcade and standard chemo. If successful, results from the pivotal trial could eventually support the company's first New Drug Application,
AUPH (T/$10-14) ...treatment lupus nephritis... BLRX (T/$3)... stem cell etal... 
***BIOC cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample.... NSTG NanoString Tech (biotech)
**BLFS  hypothermic storage and cryopreservation cells and tissues, reduce post-preservation necrosis and apoptosis...Bothel,Wa.
NAVB... Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages.
MRUS  in Phase 1/2 across three different indications — breast, colorectal and ovarian cancer — and based on data 
OPGN OpGen... VAL-083, an oncology drug for the treatment of refractory glioblastoma multiforme. The company is set to meet with the FDA before the close of the quarter to discuss a Phase 3 study design and has already picked up orphan designation for the drug. On May 5, DelMar reported the closing of a private placement that saw the company pick up gross proceeds of $5.6 million. No company, biotech or otherwise, raises equity-based capital specifically to drive sales efforts if it doesn’t believe there is a thriving market for the product. That OpGen has picked now to raise in order to spend on marketing, and that markets have been responsive to its issue, is indicative of recovery.
 SGYP...3 PATENTS... PIRS...Pirs Pharma ... EPZM Epizyme...ABEO Abeona Therapeutics ... 
DRRX (T/$3) Durect Corp... NVCR wearable electric field device for treating glioblastoma brain cancer...proprietary therapy called TTFields for the treatment of solid tumor cancers. NovoCure believes it will establish TTFields as an important new treatment modality for a variety of solid cancer tumors by increasing survival without increasing side effects when used in combination with other modalities. 
***ARQL...? ....AVEO (T/$3) ...
EDGE ... 
SNY ...the "immortality gene" treats cholestrol in adults hypercholestrolemia
Gene Therapy

***EDIT  (T/$33-65???) Editas Medicine...($18 PIVOTBuy rating and $65  price target by Chardan. Biotechnology...the ability to play God...gene therapy.... Editas Medicine is a company that should be on a lot of radars, as they’re working on a revolutionary method of genome editing which could conceivably provide cures for the approximately 6,000 diseases which are caused by genetic mutations in our DNA. Of those, only about 5% currently have approved therapeutic treatments (and those don’t address the root cause, but seek to combat the symptoms). Editas’ genome editing platform CRISPR could instead be used to correct the genetic problem at its source: right in our DNA. A protein-RNA complex can be tailored to either repair or replace damaged genetic sequences, and is then guided to the target spot in the genetic link by a guide RNA. The result is a corrected sequence that could completely cure the issues that were being caused by the defect.There are a couple issues surrounding the company however. Firstly, it could be years before any human trials of the platform are launched. Secondly, Editas Medicine is currently caught in the middle of a heated patent dispute over the CRISPR platform itself, which teams of scientists from Berkeley and the Broad Institute each claim to have the patent rights to. Interestingly, members of both of those teams helped found Editas and still serve as founding scientific advisors for the company.Setting aside the patent dispute, there’s some exciting work being done at Editas that could revolutionize medicine, making this one of the most interesting companies in the world.

CRSP  CRISPER Therapeutics AG (Buy rating and price target $23.50  by Chardan Capital)  ... focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The CRISPR/Cas9 technology allows for changes to genomic DNA. The company has strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in other diseases. It operates in Switzerland, the United States, and the United Kingdom. CRISPR Therapeutics AG is headquartered in Basel, Switzerland. Both sides claim victory — angling for millions in potential royalties and licenses — in gene-editing patent dispute 02/16/2017

§***NTLA Intellia Therapeutics Buy rating and price target $19  by Chardan....Its lead target is liver disease ...Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product ...headquartered in Cambridge, Massachusetts.
ABEO (T/$15H) gene therapies for life-threatening rare genetic diseases

Pain Relief 
KMPH (T/$8) lead product candidates are an extended release d-threo-methylphenidate product for the treatment of ADHD;  an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. ...also involved in developing a prodrug of hydromorphone for the management of pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. 
***CARA (T/$20-35) ...The company's most advanced product is CR845, an injectable kappa opioid receptor agonist intended for the treatment of acute pain. What makes CR845 special is that unlike traditional pain relief medications (opioids), CR845 targets the "kappa" receptor rather than the "mu" receptor. This means that the drug provides pain relief without many of the side effects associated with traditional opioid therapies such as nausea, vomiting, and respiratory depression. Moreover, because CR845 only acts in the periphery (it cannot enter the brain and spinal cord), the drug is unable to create any of the "euphoric" side effects of traditional opioid pain medications. In layman's terms, this means that CR845 has the potential to provide a non-addictive form of pain relief with fewer of the side effects associated with traditional therapy....03/20...=issues 5 million shares. ...
***TRVN (T/$11-14) intends to commercialize therapeutics for G protein coupled receptors. The company's central nervous system product pipeline includes Oliceridine, a small molecule G protein biased ligand, which is in Phase III clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment refractory migraine. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase IIb clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. ...
****REPH...(T/$12-21 Nov.2016)Recro Pharma, pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain.
NKTR...  *****PTIE safer oxycontin... EGLT... INSY... 
**IPCI (T/) pharmaceutical company,...patent on a way to control overdose of prescribed narcotic medications.
KALV  Phase III clinical trial designed to provide rapid sustained relief from pain associated with osteoarthritis...
NEOS ...Neos Therapeutics...extended relase oral tablets ... RDHL ...STML...blood cancers...SGYP... ABEO...AST   spinal cord injuries and cancer ... CBIO hemophilia

Zika virus
*BCRX (T/$6H)... XON(T$40)... INO (T/$13) biopharmaceutical, zika virus, Ebola... ***CERS 3.00(T/$9)...   SNY...drug manufactures

Medical/Robotics/Equip The robotic-surgery space is forecast to explode at a compound annual growth rate of more than 22% over the next five years, making it one of the fastest-growing industries in the healthcare sector. Nov. 1,2016
*****MBOT MicroBot Medical... U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key technology patent.  The Patent App. No. 14/348,610, covers a device for the prevention of shunt stenosis.  Micro-robotic technologies... Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH); and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures.
**MZOR (T/30H)...Mazor Robotics
****TRXC (T/$2) commercialization of surgical robotic systems 
TITXF () robotic surgical system for application in minimally invasive surgery...
STXS robotic systems and instruments for the treatment of abnormal heart rhythms...“The Niobe system is perhaps the most revolutionary invention in the field of cardiac ablation, enabling remote anatomic mapping of electrical currents and eradication of difficult-to-reach arrhythmias with unparalleled safety and pinpoint precision,” said Tung. “Our acquisition of Stereotaxis’ latest generation remote magnetic navigation platform will enhance a highly respected electrophysiology (EP) program that is regarded as a global leader in ablation therapy, research and education, especially in the treatment of ventricular tachycardia (VT), and will greatly improve patients’ lives.”
*EDAP High Intensity Focused Ultrasound (HIFU)(kidney stones, and Urology Devices and Services. AMDA(T/$1.50)
ISRG Intuitive Surgical ...
****ERBA diagnostic test kits automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology, and diabetes testing...
 NVTR (T/$10) CyBorg technology...neuroscience...
***MLSS (T/$4)  STA Single Tooth Anesthesia Instrument, a computer-controlled local anesthesia delivery instrument that incorporates the pressure feedback elements of its patented CompuFlo technology, which allows dentists to administer injections into the periodontal ligament space; and CompuDent, a computer-controlled local anesthetic delivery instrument that provides painless injections for various routine dental treatments, including root canals, crowns, fillings, and cleanings. Its products also comprise CompuMed, a computer-controlled injection instrument for use in various applications, such as colorectal surgery, podiatry, dermatology, cosmetic surgery, hair restoration surgery, nasal and sinus surgery, orthopedics, and others. In addition, the company provides The Wand, a hand piece that allows bi-directional rotation during injection, which prevents needle deflection that occurs with a traditional syringe.
CTSO target $10...Cytosorbents Corp  a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

NUVA () Minimally invasive spinal surgery MDT... JNJ...PHG...SYK...ZBH
XTNT  (T/$1.50) orthrobiologics
Other Medical
***CYTR() CytRx Corp...Soft tissue sarcoma is a cancer occurring in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. It can arise anywhere in the body at any age. STS remains a high unmet medical need because of the difficulty in treating the more than 50 types of this aggressive cancer. According to the American Cancer Society, in 2016 more than 12,300 new cases were diagnosed in the U.S. and approximately 5,000 Americans died from this disease.  In addition, approximately 40,000 new cases and 13,000 deaths in the U.S. and Europe are part of a growing underserved market. Recently, the company announced the U.S. Food and Drug Administration reached an agreement with CytRx on preparations for a New Drug Application submission for aldoxorubicin in soft tissue sarcomas. 2017 American Society of Clinical Oncology (ASCO) Annual Meeting...the data presented at ASCO this year demonstrate that, unlike any other drugs in this class, aldoxorubicin can be dosed continuously with minimal to no cardiotoxicity," commented Sant Chawla, M.D., F.R.A.C.P., Director of the Sarcoma Oncology Center in Santa Monica, California, and Principal Investigator for the Phase 3 trial.
NVCR (T/$15) Mesothelioma
CSLT (T/$5.50) ...operates a health benefits platform in the United States.
PIRS...Pirs Pharma... §EPZM Epizyme...KPTI  Karyopharm ... ABEO Abeona Therapeutics ...
XTNT (T/$1.50) OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC to fill bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with fusion, as well as could be used in conjunction with a hardware plate system. The company also provides BacFast HD facet stabilization dowels; OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; hMatrix dermal scaffold, an acellular matrix made from donated human dermal tissue that is used to replace a patient's damaged tissue
***HLTH (T/$2.50)...outpatient surgery facilities... 
KITE (T-77H) removes a person’s T-cells, engineers them to seek and destroy cancer, multiplies them by the billions then re-introduces them into the body. And although early stage, the results thus far have been extremely positive. KITE is currently conducting a phase I study of their cell therapy in patients with non-Hodgkin lymphoma, has made positive remarks about the progress in press releases and plans to present all of the data at the American Society of Hematology in December— this could potentially be market moving news so traders may look to position themselves accordingly. CAR-T therapy is based on extracting immune system cells out of the patient’s body, fabricating them and infusing them back into the patient’s body to identify and fight the cancer. While the therapy has shown successful results for treating blood cancers, its use has not yielded the desired success for treating solid tumors. Solid tumors are usually an abnormal mass of tissue that may be benign (non-cancerous), or malignant (cancerous). They are classified as sarcomas, carcinomas and lymphomas depending upon the type of cells that form them. The researchers at the University of Pennsylvania's Perelman School of Medicine indicated that CAR-T therapy using double target can be applied for treating a wide range of solid tumors. The combination treatment involved fabricating the T-cells to target a cancer-associated surface protein with shortened carbohydrate molecules. The double-target therapy showed high effectiveness of using new CAR’s in mouse models of pancreatic cancer.
CLDX biotech... EXEL Exelixis biotech... 
 AMDA (T/$2-5 )biomaterialsValeo silicon nitride spinal fusion devices.(additional shares/dilution Jan 2017 $0.51...
MIBC... RIGL ... OMER ...
PSDV (T/$7)
IMGN (T/$6)

ADMP...Adamis Is a Dark Horse Trotting to Win in the EpiPen Arena
Adamis has a vision for its Epinephrine Pre-filled Syringe “PFS," which is designed as a cost-friendly alternative for those suffering from anaphylactic reactions. The drug maker hopes to compete with the likes of Mylan's EpiPen that has been raking in billions.

With the FDA's decision expected on June 15, Maxim analyst Jason Kolbert seems to not be concerned by the Complete Response Letter the company received from the regulator last year. While the FDA expressed concerns and pushed the firm to work on expansion of the human factors study, Adamis has since handled these challenges successfully. The expansion was just a "low hurdle" to the analyst, as he does not see this to be a meaningful roadblock in any way to Adamis' success.

The analyst is also excited about the market opportunity the company is pursuing, noting, "We see a billion dollar market, and in Adamis PFS a superior product [...] If Adamis can acquire just 10% market share and generate sales approaching $100M (which we believe is the low end), it suggests shares are undervalued."

Ultimately, Kolbert believes Adamis' valuation is compelling: "At a sub-$100M market capitalization and with what we believe should be the next version of an EpiPen-like product (PFS), plus a pipeline of respiratory products and compounding pharmacy revenues set to build, we see Adamis as poised for a breakout year in 2017."

As such, the analyst reiterates a Buy rating on Adamis shares, with a $10.00 price target, which implies 185% potential upside from current levels
***ERII 7.50(T/$16-21)energy recovery devices, turbochargers for water desalination/makes equipment for oilfield that makes fracking more efficient .. . 
*AMSC (T/$10-11) now in doubtwind turbine systems... RVLT   (T/$?) sells light emitting diode (LED) lighting solutions...
MNGA (T/$1.50) converts liquid waste into hydrogen based fuels.. *CWST (T/$13H)water treatment... *HCCI (T/16H) oil clean up parts cleaning...
***MXWL  (ultra Capacitors) .. energy storage and power delivery products, ultra-capacitor cells...  
CDTI CDTI  (T/$4) diesel emissions control systems...
***ARTX artx (T/$5)defense and security products sells rechargeable and primary batteries, and smart chargers to the military...
***OPTT (5.3 million share dilution Apr 27)...ocean wave electricity... VTNR  recycle industrial waste... FF biofuel
SPCL (Google finance)...Solaris Power Cells, Inc. is a developmental stage diversified "Green" Energy Storage manufacturer offering residential and commercial users turnkey, renewable energy storage solutions (ESS). Solaris manufactures the Solaris PESA™ "Passive Electron Storage Array"™, for limited use electric vehicles such as golf cars and Mega Energy Storage Systems. (ESS) The Solaris PESA™ is a 100% lead-free, solid-state storage (ESS) solution that makes renewable energy greener and better by allowing applications to utilize more of the energy generated. The Solaris Power Cell™ is capable of providing energy storage to applications normally reliant and equipped with highly toxic lead acid, nickel metal hydride or lithium-ion batteries. home...
ECR (T/$3
NGPHF  NGPHF Northern Graphite.. *GPHOF .....***FCSMF... *ZENYF ....
Over the next two years 2016-2018, 25 new makes and models of electric cars are expected to be released. BYD Co. Ltd BYDDF and Tesla TSLA currently lead global sales.
LIT  CandleGlance...

Right now, most of the world’s lithium is being produced in Australia, Chile, Argentina, and China.

Australia has the largest production by far, coming in at 14,300 tons in 2016, according to the U.S. Geological Survey. Most of Australia’s production comes from hard-rock mines.

Chile comes in second place with 10,500 tons, mainly from brine operations in the Salar de Atacama, the country’s largest salt flat.

Chile has the world’s largest lithium reserves held in these briny deserts: 7.5 million tons of our metal oil just waiting to be extracted!

Despite these high numbers, it’s the last two countries that will be getting all the attention soon.

Argentina, with 5,700 tons of production and 2 million tons in reserve. 

Argentina, meanwhile, has recently opened its doors to a new slew of lithium miners.

China, with production at 2,000 tons and reserves around 3.2 million tons, are both looking to ramp up production to meet demand. China already imports much of its lithium supplies from Australian mines. A sudden boom in demand for electric vehicles actually caused a shortage in 2016 and prompted officials to look at increasing domestic production.

... it’s lithium’s difficult nature that makes it so valuable. It’s not rare; it’s just hard to get in the quantities we’re going to need. Which makes Lowry’s point all the more salient: the best thing for the lithium revolution now is to start getting some actual results out of all the energy industry’s talk.

*****SQM...SQM is forcefully exerting its dominant position as the lowest cost, highestmargin incumbent lithium producer with aggressive growth plans in Argentina(09/05/16).
 FMC....**ALB (T/$94H)...  AMLM ()....*****LIXXF ()... AABVF  §*****LACDF (T/$1.30)Lithium ;Kings Valley Project located in northwestern Nevada... 

  ***NMKEF ... ******GALXF...***LIEG... SNET rare earths  and lithium... CRE.V Critical Elements lithium and rare earths Quebec..
*****ORRP () Lithium mine/Nevada... *****OROCF Orocobre...  ILHMF... RCKTF... HREEF... DJIFF... SRCAF... SNNAF... CYDVF
 SSMLF Nevada Energy Metals ......  (BCN.V) (BCRMF Bacanora ***. URRE... ***PE.V Pure Energy Materials...  CYP.V  Cypress Development Corp tiny company... 
***AVLIF Advantage Lithium... ILC.V....PEMIF...PKX (Korean steel and now add lithium...
***NEV.V Nevada Sunrise Gold ...   LTUM Lithium Corp Nevada   DJIFF Dajin Resources  a minnow now in the lithium space, but their extensive holdings in the lithium triangle are truly astounding. They have some nice Nevada properties as well.
*****ALTAF()(T/$0.30) Altura Mining Australia()... RRSSF Neometals (BCRMF() Bacanora Minerals ? ROCEF Lithium X...
The three largest lithium producers are the Chile-based Sociedad Quimica y Minera (SQM), American FMC Lithium (FMC), which controls the ominously-named Hombre Muerte mine in Argentina, and Albermarle (ALB). 3 companies produce 90% of the world’s lithium with SQM controlling one third of all the world’s lithium reserves.
**PCRFY PCRFY Panasonic Corporation...*KNDI electric vehicle China...GELYF Geely Holding Co..BYDDF Electric vehicle China ...
EGTYF Eguana... 
 TANH electric vehicles and power batteries ...
*ULBI lithium battery (CBAK-US, OGES-US, UPGI-US, EPC-US and HRG-US)...CCGI electric v ehicle (EV) charging stations ...ENS EnerSys
*HPJ (T/$12.78) lithium,and nickel metal hydride rechargeable batteries... ..*.OGES  lithium ion large format prismatic cells; small format prismatic cells; and battery modules.
OTHER/Related... RDRUY Neometals...LGEAF Korean Battery... FT.TO Fortune Minerals... LUN.TO Lundin Mining...EFLVF Electrovaya
Energy Storage companies - A new and developing area, so not easy to pick the winners here. Certainly the major battery manufacturers and lithium miners discussed above can benefit. Numerous others to choose from include... 
****ENPH Enphase Energy (T/$4) recent Sept. 23, 2016 secondary stock offering=dilution The company's semiconductor-based microinverter system converts direct current electricity to alternating current (AC) electricity at the individual solar module level. The Enphase AC Battery is a key component of the Enphase Home Energy Solution, the industry's first and only truly integrated offering that combines solar generation, energy control, and storage, and provides homeowners the unique ability to manage their solar and storage together in an integrated fashion. 
Advanced Microgrid Solutions (private ), Fronius (private), Imergy (private), Redflow (ASX:RFX), AES Corp. (NYSE:AES), NEC (OTC:NIPNF), Sharp (OTCPK:SHCAY), Younicos (private, interest held by First Solar), Southern California Edison (SCE), General Electric (NYSE:GE), EnerSys (NYSE:ENS), Johnson Controls (NYSE:JCI), Sony (NYSE:SNE), Sonnen (private) and Origin Energy (NASDAQ:ORG).
Electrovaya (EFL.TO) could well be the little company that could. Developer and manufacturer of portable Lithium-ion battery power solutions for the automotive, power grid, medical and mobile device sectors. The company is based in Mississauga, Ontario, Canada

AES (T/$12) AES Corp... Utility-scale energy storage is expected to surpass 1.6 gigawatts by 2020, edging out the old grid system and making it that much easier to integrate more renewable capacity — once the tech catches up! San Diego Gas & Electric chose a battery design by AES Corp. (NYSE: AES) to begin replacing one of its largest natural gas peaking plants with as much as 300 megawatts of battery storage. The company will also be upgrading the existing plant, but it notes that the end goal is to replace it with renewables later on. Southern California Edison has also contracted Tesla, in a move that should surprise no one by now, to continue building onto its existing 80-megawatt energy storage project in Mira Loma. The system is already online as of this year and can cover peak energy demand for as many as 15,000 California homes. Right now, it’s the biggest lithium battery station operating in the U.S. As it stands, electric cars are still set to be the biggest source of growth in lithium batteries in coming years, but that view could shift if this trend gains traction...
LIT Lithium research 

New Battery better than Lithium...John Goodenough, the 94-year-old father of the lithium-ion battery

ECSIF eCobalt Solutions... Cobalt metal
Cobalt metal is in high demand due to growth in the electric vehicle ("EV") market, which uses lithium-ion batteries to power these vehicles (cobalt being a main component). In conjunction, its growing supply deficit is leading the price of the commodity higher. Macquarie Research projected a supply deficit of 885 tonnes in 2018, 3,205 in 2019, and 5,340 in 2020. That comes to a supply deficit increase of 6x in just two years. For large-cap tech companies and automakers looking to produce electric vehicles, the need for cobalt has become increasingly clear given its role in the lithium-ion battery mix. The metal constitutes a little over one-third of a modern lithium-ion battery's composition (and greater than the amount of lithium used itself).
How the competition is doing - Larger mining companies also have cobalt operations ongoing, including Freeport-McMoRan (NYSE:FCX) (T/$12-16), Katanga Mining (OTCPK:KATFF), Glencore (GLCNF), Fortune Minerals (OTCQX:FTMDF), Barra Resources (OTC:BRCSF), Tiger Resources (OTC:TRSDF), Lundin Mining (LUNMF), and Cruz Cobalt Corp. (OTCPK:BKTPF).

Types of Fuel Cells
Ceramic/Solid Oxide Fuel Cells 
BLDP..*PLUG (T/$2h)...**FCEL ...****HYGS .HYGS Hydrogenics
CEFLF ...Ceramic Fuel Cell... CPWHF... NPWZ... HFCO... SSMFF... ITMPF... EVOMF

Solar.... financer and installer...
CAFD (T/$15) November 30, 2015, it owned interests in six utility-scale solar energy projects, two commercial and industrial solar energy projects, and a portfolio of approximately 5,900 residential solar installations with a total capacity of 432 megawatts.
WNDW Solar Window Tech.
RGSE ....02/06 ...$11million dilution and price goes UP... RUN 


AMSC (T/$9) Wind and electrical grid... utility
SMH CandleGlance Semiconductor ...AMD,MVDA,CY,IDTI,IPHI,MPWR,MU,MXIM,TXN,LLTC  ....
SEMI... AIXG (equip Germany) ... ACLS... Semiconductor equip. and materials... TSEM analog intensive mixed-signal semiconductor devices...
CVV (equip) ...materials or coatings for aerospace engine components, medical implants, semiconductors, solar cells, smart glass, carbon nanotubes, nanowires, LEDs, MEMS, and other applications.
LEDS... SemiLEDs Corporation develops, manufactures, and sells light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights, as well as commercial, industrial, and residential lighting; and specialty industrial applications, such as ultraviolet (UV) applications, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection....Taiwan.
***MU semiconductor systems ..... CY CypressSemi

SINO ...air delivery and frieght services
****SFL (T/$16) 11% dividend... fleet of 16 oil tankers, 22 dry bulk carriers, 20 container vessels, 2 car carriers, 2 jack-up drilling rigs, 2 ultra-deepwater drilling units, 5 offshore supply vessels, 2 chemical tankers, and 2 newbuilding oil pro duct tankers. 
**GMLP...(T/$23)Golar LNG Partners LP owns and operates floating storage regasification units (FSRUs) and liquefied natural gas (LNG) carriers under long-term charters in Brazil, the United Arab Emirates, Indonesia, and Kuwait.
***ASC (T/$10) LNG/LPG carriers 10.68% DIVIDEND(0.71)...**DHT (T/$5H, 6)(0.46bk) oil tankers...
 ***TK () crude oil and LNG has $10.81 cash a share, Dividend% 3.20%. TNP (T/$6)
**DSX (T/$3H, 5)  shipping...***DCIX (T/$8) CONTAINER...***DRYS(T$2.53...1.64bk) dry bulk ... **EGLE...(0.04bk) dry bulk...
***ESEA () dry bulk/containers...***GLBS (0.49bk)dry bulk,...**GNK (T/$11H) dry bulk, company has 6.51share in cash... **NMM... dry bulk...  
***SALT dry bulk,
 has $3 a share in cash... SHIP() dry bulk...TOPS (0.34bk) oil tankers...**GASS grude oil and liquefied petroleum gas (LPG) 
ANW shipping, LNG/LPG carriers a marine fuel logistics company markets supplies refined marine fuel and lubricants to vessels in port, at sea, rivers, worldwide ...

Other Stocks 
CELP  (T/$8) oil gas equip. and services...
INFN (T/$12-13)
NSSC (T/$12) security softwar and devices...
ATTO (T/$14)
CPSH ...produces and sells advanced material solutions to transportation, automotive, energy, computing/Internet, telecommunication, aerospace, defense, and oil and gas markets. Its products are used in applications that involve energy use or energy generation. The company primarily offers metal matrix composites that are a combination of metal and ceramic, such as baseplates for various applications, including motor controllers used in electric trains, subway cars, wind turbines, and hybrid and electric vehicles; baseplates and housings for use in radar, satellite, and avionics applications, as well as in modules built with wide band gap semiconductors; and lids and heatspreaders used with integrated circuits for use in Internet switches and routers. It also assembles housings and packages for hybrid circuits. CPS Technologies Corporation primarily sells its products to microelectronics systems companies in the United States
SVU (T/$5.50-6) wholesale and retail grocer...
***KTOS KTOS..(T/$7H) ... provides unmanned aerial, ground, seaborne, command, control, and communications systems.
CCIH  provider of Internet content and application delivery services and cloud in China......
ESES oil/gas service
AMRS ...bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable hydrocarbons.
*****LQMT () amorphous metal ( metallic glass/glassy metal) solid metallic material, usually an alloy, disordered atomic-scale structure.
****LKAI () mining/explores for gold, silver, lead, and zinc metals...  NIOBF () niobium/scandium/titanium project located in Nebraska...
GARWF ()Golden Arrow Resources gold, silver, lead, zinc, and copper. CHNR iron, zinc, and other nonferrous metals in the Peoples Republic of China 
*CRESY agriculture Argentina... INGN oxygen concentrators
**UAMY.. produces and sells antimony, silver, gold, and zeolite products in the United States. The company's Antimony division offers antimony oxide that is primarily used in conjunction with a halogen to form a synergistic flame retardant system for plastics, rubber, fiberglass, textile good...
**AUO liquid crystal displays and other flat panel displays, solar and water re-cycling
JVA. Coffee...   WPX... independent oil and natural gas exploration and production.
(Google)***DMPID ... commercializing anti-cancer therapies ...  
***BTE ...oil Eagle Ford... BRCD Brocade Commucations/Ruckus ...ROX...sells beverage alcohol products in the United States and internationally
BKD  ($T/16H) senior living ...IPAS Telecom Services...  GRMX... IIN...(T/$11) body worn devices...micro-miniature electronics and hearing aids
ZNGA (T/3.50) games... SFE venture capital... GSVC...venture capital pre-IPO... FMCC  Freddie Mac ... FNMA Fannie Mae
NE (T/$7.50) ... SSKN (T/$12?)... VRAY (T/$11)
Larger Cap. Speculation...  
EA (T/$92H-102H) Electronic Arts... NUVA (T/$72H) NuVasive Medical Appliance/equip... ETSY (T/$15) arts/crafts online sellers... UBNT (T/$60-66) Ubiquiti wireless equipment... ALGN (T/$110H) AlignMed. Appliance/equip dental...BOFI (T/$33) bank of internet Bofl Holdings savings and loan... ADRO (T/18) Biotech 
(T/29) Biotech... INFN (T/$13.50) Commctn Equip...

UA (T/$30) Under Armour apparel clothing... ***SQ (T/$20)Mobile payment services
WDAY (T/$85H) Workday financial software cloud...   PI (T/$40H) IMPINJ Commmunication equip...

Marijuana Stocks

Marijuana Stock Scams
Inside The Pot Stock Bubble
Cannabis gold rush

The Very First Marijuana Stock ETF Has Lost Investors Money

There's no two ways about it: As an investor, you'd struggle to find an industry with a more appetizing long-term growth rate than legal marijuana.

According to cannabis research firm ArcView, North American legal sales increased by 34%, to $6.9 billion in 2016, albeit black-market sales still totaled $46.4 billion. As more U.S. states push to legalize, and with Canada potentially on the precipice of legalization by 2018, the expectation is more that this $46 billion-plus in illicit sales will shift to the legal and regulated markets in the years to come.

By 2026, investment firm Cowen & Co. anticipates total legal sales could reach $50 billion. If that's the case, we're talking about more than 23% annual growth for a decade. It's these figures that are attracting businesses and investors to marijuana stocks in droves.

HMMJ.TO Medical Marijauna Life Science ETF

MJNA medical marijuana and industrial hemp...
HEMP *HEMP marijuana industries...  *** CANN General Cannabis... VNNYF... VPRB... UBQU... MCIG... INSY... CARA ...APHQF... TWMJF... 
 *DIGP cannabis testing; and provides cannabis news with a news/talk radio, ... IGC cannabinoid based biopharmaceutical for end of life supportive care,India...
****INSY ...T-$22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol...   *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...

GRNH GreenGro greenhouse/growing equiptment....
KNDI...China electric one time this stock traded above $ 2017 there are a ton of law suits after Kandi Technologies ass.

Now what Feb. 14, 2017

With the subsidy-payment drama now behind the company, its focus will be on developing new vehicles that won't rely solely on subsidy payments to be economically viable. Kandi is currently developing those EV products for after 2020, when the subsidy payments end. The company also has its hands full launching two new EV models this year and preparing its car-making joint venture company for its initial public offering.

This will be a pivotal year for Kandi and its investors. But don't expect its stock price to regain its lost value until management proves it can take steps to reduce its reliance on subsidy payments while reigniting its revenue.


Daniel Miller has no position in any stocks mentioned. The Motley Fool
On 22 August 2016. Kandi Technologies Group, Inc. (NASDAQ:KNDI) announced that Kandi Electric Vehicles Group Co., Ltd. (the “JV Company,” a 50/50 joint venture between Kandi and Geely Automobile Holdings Ltd.) has unveiled its new pure electric vehicle (“EV”) model named the “Global Hawk K21.” This new all-electric sedan is equipped with automatic braking technology, a voice control system, a infotainment system, remote software update capabilities, and a fully-integrated electrical control system. Packaged with the ternary battery, the vehicle has a top speed of 100+ km/h and a driving range exceeding 150km on a single full charge. The Global Hawk K21 joins the ranks of mid-tier luxury pure electric vehicles offered by the JV Company.

An Electric Car Vending Machine
Four-Passenger Pure Electric Sedan Vehicle


Marijuana Stocks

Marijuana Stock Scams
Inside The Pot Stock Bubble
Cannabis gold rush
HEMP *HEMP marijuana industries... GRNH GreenGro greenhouse/growing equiptment.... MJNA medical marijuana and industrial hemp...*** CANN General Cannabis
 *DIGP cannabis testing; and provides cannabis news with a news/talk radio, ... IGC cannabinoid based biopharmaceutical for end of life supportive care,India...
****INSY ...T-$22 MEDICAL MARIJUANA, synthesized marijuana cannabidiol...   *VRTHF...medical marijuana...CBDS...Cannabis Sativa... HMPQ Hemp America...
I long ago concluded that regression to the mean is the most powerful law in financial physics: Periods of above-average performance are inevitably followed by below-average returns, and bad times inevitably set the stage for surprisingly good performance.

These are ten of Bob Farrell’s most famous observations:
1. “Markets tend to return to the mean over time.”  For those of you who’ve taken statistics, you know exactly what this refers to:  stocks often move too far in one direction as euphoria or pessimism clouds people’s thinking.  Investors lose perspective and start believing the little devil on their shoulders.
2. “Excesses in one direction will lead to an opposite excess in the other direction.”  I think of it like bungee jumpers whose cords stretch out and then compress multiple times before they come to rest or achieve equilibrium.
3. “There are no new eras – excesses are never permanent.”  As the latest hot sector climbs higher and higher, you inevitably hear variations of the chorus shouting “it’s different this time”.  Of course, human nature does not change so it never really turns out to be any different.
 4. “Exponential rapidly rising or falling markets usually go further than you think, but they do not correct by going sideways.”  The smart money locks in profits which leads to significant selling and inevitably to a correction.
5.“The public buys the most at the top and the least at the bottom.”  It’s been this way since humans invented commerce.
6.“Fear and greed are stronger than long-term resolve.”  Research in behavioral finance has shown that stock market gains make us exuberant; they enhance well-being and promote optimism which makes investors like to buy.  Losses, on the other hand, bring sadness, disgust, fear and regret.  Fear increases the sense of risk which thereby makes investors shun stocks.
7.“Markets are strongest when they are broad and weakest when they narrow to a handful of equities.”  Think of it as strength in numbers.  Broad breadth (i.e. market participation) and big volume is important.  When wide ranging momentum channels into a small number of stocks, the top is near.
8.“Bear markets have three stages – sharp down move, reflexive rebound and a drawn-out fundamental downtrend.”  
9.“When all the experts and forecasts agree, something else is going to happen.”  Farrell suggests that patient buyers who raise cash in frothy markets and reinvest when sentiment is darkest can profit nicely.
10.“Bull markets are more fun than bear markets.”  It has been my observation that historically the markets have rewarded optimists to a far larger degree than pessimists.  I prefer to play in the bulls’ camp.
Trade well; trade with discipline!-- Gatis Roze

Linda Raschke's 12 Rules for Technical Trading.
1. Buy the first pullback after a new high. Sell the first rally after a new low. 
2. Afternoon strength or weakness should have follow through the next day. 
3. The best trading reversals occur in the morning, not the afternoon. 
4. The larger the market gaps, the greater the odds of continuation and a trend. 
5. The way the market trades around the previous day’s high or low is a good indicator of the market’s technical strength or weakness. 
6. The previous day’s high and low are two very important “pivot” points, for this was the definitive point where buyers or sellers came in the day before. Look for the market to either test and reverse off these points, or push through and show signs of continuation. 
7. The last hour often tells the truth about how strong a trend truly is. “Smart” money shows their hand in the last hour, continuing to mark positions in their favor. As long as a market is having consecutive strong closes, look for up-trend to continue. The up trend is most likely to end when there is a morning rally first, followed by a weak close. 
8. High volume on the close implies continuation the next morning in the direction of the last half-hour. In a strongly trending market, look for resumption of the trend in the last hour. 
9. The first hour’s range establishes the framework for the rest of the trading day
10. A greater percentage of the day’s range occurs in the first hour then was the case in the past, and thus it has become increasingly important to trade aggressively if there are early signs of a strong trend for the day. 
11. There are four basic principles of price behavior which have held up over time. Confidence that a type of price action is a true principle is what allows a trader to develop a systematic approach. The following four principles can be modeled and quantified and hold true for all time frames, all markets. The majority of patterns or systems that have a demonstrable edge are based on one of these four enduring principles of price behavior. Charles Dow was one of the first to touch on them in his writings. 
Principle One: A Trend Has a Higher Probability of Continuation than Reversal 
Principle Two: Momentum Precedes Price 
Principle Three: Trends End in a Climax 
Principle Four: The Market Alternates between Range Expansion and Range Contraction! 
12. In the world of money, which is a world shaped by human behavior, nobody has the foggiest notion of what will happen in the future. Mark that word – Nobody! Thus the successful trader does not base moves on what supposedly will happen but reacts instead to what does happen.

To better understand and appreciate the trading systems seen on this board

Break a bad habit
 "The truth is that trading, both successful and unsuccessful, is more about psychology than tactics." - Jack Schwager

Multicollinearity... Bollinger Bands... CCI...
NOISE...RANDOM...CHAOS...ORDER...STRUCTURE ...if you don't know where you are will you know where you're going?
Structure= creates Order out of CHAOS
Keep Keeping It Simple...Buy low...Sell high...relative to what...? (one day will edit)
Patience...Moving averages...CONFLUENCE..

3day moving average study...Grail QUESTion may cure that gambler in you...with understanding ...gambling/fear gets replaced with confidence and patience...

SLV...3 cross 5 moving average

Adapting Moving Averages to Market Action

Quest of the TREND
Definition for TREND...and...Momentum
Volume speaks VOLUMES...
Momentum volume and momentum Stochastics
Accumulation/Distribution and how to use the Candle Glance Charts
Price gaps occur when the range of a price bar does not include the range of the previous bar. It acts as a reliable level of support and resistance for subsequent price action and should always be monitored.

Does Momentum Investing Work?
Momentum Investing With ETFs
!PMOBUYALL...Percentage of PMO Crossover Buy Signals
Sentiment Extreme Gold Silver

$VIX... "Black Swan"
#30  Sticky Note 60 minute Sectors kiy 05/18/17 02:02:50 PM
#38   HMMJ.TO... The Very First Marijuana Stock ETF Has kiy 05/27/17 09:54:01 PM
#37   CYTR...although overbought right now,CYTR looks interesting on any drawdowns... kiy 05/27/17 04:37:50 PM
#36   JO Coffee ETN may have some triggers starting... kiy 05/26/17 09:56:25 PM
#35   ZPAS... kiy 05/23/17 11:25:40 AM
#34   WNDW solar... kiy 05/23/17 10:55:31 AM
#32   AXSM – Receives Fast Track designation from the kiy 05/21/17 07:44:44 PM
#31   XTLY is having a nice run going into kiy 05/21/17 04:03:19 PM
#30   60 minute Sectors kiy 05/18/17 02:02:50 PM
#29   ECSIF eCobalt Solutions... Cobalt metal...Price has found centerline kiy 05/16/17 07:24:43 PM
#28   EDIT...when I saw Chardan Capital Markets price target kiy 05/16/17 05:03:30 PM
#27   ADMP...Adamis Is a Dark Horse Trotting to Win kiy 05/15/17 10:20:20 PM
#26   CPE...Callon Petroleum...some joker has an $18 target on kiy 05/15/17 07:03:25 PM
#25   AUY ...has a price target of $3.50-4.00 better kiy 05/15/17 05:48:53 PM
#24 range bound $6.50-$5.50...if the overall market goes kiy 05/14/17 09:47:44 PM
#23   KIY - Thanks for creating the speculation board! handsdo 05/14/17 09:12:13 PM
#22   ...the ability to play God...gene therapy.... kiy 05/14/17 03:44:00 PM
#21   Zpas...had record volume May trying to define kiy 05/12/17 11:46:37 AM
#20   HIMX...not doing that great above $7...but there will kiy 05/12/17 11:35:14 AM
#19   EXK... hit the + 10 cover 1/3 kiy 05/12/17 09:58:30 AM
#18   EXK has better internals than CHK but has kiy 05/11/17 11:20:31 PM
#17   CHK...CCI 20 has reached overbought at +100.. kiy 05/11/17 11:09:42 PM
#16   CHK...says life is good...even if the oil price kiy 05/10/17 12:48:31 PM
#15   ZPAS ZoomPass...We all knew a disruptor to financial kiy 05/09/17 11:52:13 AM
#14   Added long CHK at $5.45 hair trigger stop...not kiy 05/08/17 11:05:01 AM
#13   CHK...reported good eanings kiy 05/04/17 10:37:17 AM
#11   CHK...reports earning May 4th before the Market opens...Price kiy 05/03/17 08:11:11 PM
#10   SLV...Can't like the price action of SLV today...even kiy 05/03/17 12:21:37 PM
#9   EXK...earnings report is positive... kiy 05/03/17 10:36:26 AM
#8 has EXK reporting earnings "before the Market kiy 05/02/17 08:21:08 PM
#6   nucklebones...your post GEGI was deleted before I replied...I kiy 05/02/17 11:35:36 AM
#5   Exk is looking sweet bro at these prices nucklebones 05/02/17 11:04:56 AM
#3   Long position EXK at $'s still early...stop is kiy 05/02/17 10:12:44 AM
#2   EXK...the there a trade here...The stock answered kiy 05/01/17 05:39:13 PM
#1   EXK...Silver...BUY low/SELL high...relative to what...???... kiy 04/30/17 08:18:11 PM